Teva Announces Launch of Generic Prometrium Capsules in the United States
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Progesterone Capsules, 100 & 200 mg, the AB-rated generic equivalent of Abbott Laboratories' Prometrium Capsules.
The brand product had annual sales of approximately $197 million in the United States, based on IMS sales data.
The product is indicated for the treatment of secondary amenorrhea due to a decrease in progesterone as well as in conjunction with estrogen-containing medications in postmenopausal women with a uterus.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.